Circulating TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells are associated with efficacy of combined aPD-L1, aCTLA-4 and metronomic chemotherapy in advanced cervical cancer

To improve ICI efficacy in advanced CC, a promising strategy is to combine anti-PDL-1, anti-CTLA-4 and chemotherapy. The phase I/II MOVIE trial reported a clinical benefit rate of 53.1% of durvalumab, tremelimumab and metronomic oral vinorelbine in patients with pretreated metastatic CC. The objective of this study is to discover immune efficacy biomarkers of this combination. We analyzed 29 advanced CC patients from MOVIE multicentric prospective clinical trial (NCT03518606). We used high-dimensional mass cytometry (CyTOF) to explore the immune landscape in baseline peripheral blood mononuclear cells. We developed 3 immune panels of 40 antibodies (T cells, NK cells and myeloid cells) for the deep-phenotyping of PBMCs. Our bioinformatics workflow of CyTOF data included dimensionality reduction (opt-SNE, UMAP), automated clustering (PhenoGraph) and regression (CITRUS). The biomarker candidates were submitted to a model prediction composed of 11 machine-learning algorithms. In baseline blood samples, high-dimensional analyses consistently identified a population of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells associated with improved clinical outcomes: clinical benefit (CB), progression-free survival (PFS) and overall survival (OS). This population was confirmed by manual gating and 11 machine-learning algorithms. After determining a cut-off at 0.73% of CD45+ cells, patients with an increased blood baseline frequency of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells had an improved CBR (76% vs 25%, p=0.005), an improved PFS (HR=0.35, CI95, 0.13-0.95, p=0.013) and an improved OS (HR=0.19, CI95, 0.07-0.53, p=0.001). Multivariate analysis with classical CC prognostic factors confirmed the OS benefit of our biomarker (HR=0.15, CI95: 0.05-0.47, <0.001).

Authors

Institutions

Publication Details

Journal
Cancer Immunology Research
Published
2026-11-17
DOI
https://doi.org/10.1158/2326-6066.cir-26-0124
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Circulating TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells are associated with efficacy of combined aPD-L1, aCTLA-4 and metronomic chemotherapy in advanced cervical cancer

F. Legrand, Marie-Sarah Rouviére, Philippe Rochigneux, Anthony Gonçalvès et al.
3 links
Cancer Immunology Research
Cancer Immunotherapy and Biomarkers
article

Circulating TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells are associated with efficacy of combined aPD-L1, aCTLA-4 and metronomic chemotherapy in advanced cervical cancer

F. Legrand, Marie-Sarah Rouviére, Philippe Rochigneux, Anthony Gonçalvès, Renaud Sabatier, Amira Ben Amara, Daniel Olive, Samuel Granjeaud, Brice Chanez, Brice L Gaudilliere, Claire Cropet, Jean‐Sébastien Frenel, Antonella Bertucci, Laurent Gorvel, Alice Hervieu, Elodie Coquan, Emilien Billon, Pernelle Lavaud, Christophe Le Tourneau, Julien Jacques Hedou, Aaron Elliott Lisberg, Anne-Sophie Chrétien, Pauline Maby, Esma Saâda-Bouzid, Thibault de la Motte Rouge, Chloé Reine
article en

Abstract

To improve ICI efficacy in advanced CC, a promising strategy is to combine anti-PDL-1, anti-CTLA-4 and chemotherapy. The phase I/II MOVIE trial reported a clinical benefit rate of 53.1% of durvalumab, tremelimumab and metronomic oral vinorelbine in patients with pretreated metastatic CC. The objective of this study is to discover immune efficacy biomarkers of this combination. We analyzed 29 advanced CC patients from MOVIE multicentric prospective clinical trial (NCT03518606). We used high-dimensional mass cytometry (CyTOF) to explore the immune landscape in baseline peripheral blood mononuclear cells. We developed 3 immune panels of 40 antibodies (T cells, NK cells and myeloid cells) for the deep-phenotyping of PBMCs. Our bioinformatics workflow of CyTOF data included dimensionality reduction (opt-SNE, UMAP), automated clustering (PhenoGraph) and regression (CITRUS). The biomarker candidates were submitted to a model prediction composed of 11 machine-learning algorithms. In baseline blood samples, high-dimensional analyses consistently identified a population of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells associated with improved clinical outcomes: clinical benefit (CB), progression-free survival (PFS) and overall survival (OS). This population was confirmed by manual gating and 11 machine-learning algorithms. After determining a cut-off at 0.73% of CD45+ cells, patients with an increased blood baseline frequency of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells had an improved CBR (76% vs 25%, p=0.005), an improved PFS (HR=0.35, CI95, 0.13-0.95, p=0.013) and an improved OS (HR=0.19, CI95, 0.07-0.53, p=0.001). Multivariate analysis with classical CC prognostic factors confirmed the OS benefit of our biomarker (HR=0.15, CI95: 0.05-0.47, <0.001).

Cancer Immunology Research
Inserm (FR), University of California, Los Angeles (US), Institut Gustave Roussy (FR), Université Rennes 2 (FR), Centre Georges François Leclerc (FR), Centre François Baclesse (LU), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Centre François Baclesse (FR), UniCancer Group (FR), Centre de Recherche en Cancérologie de Marseille (FR), Institut Paoli-Calmettes (FR), Centre Antoine Lacassagne (FR), Institut Jean Godinot (FR), Fondation Gustave Roussy (FR), Université de Rennes (FR), Stanford University (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon